A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)

• Status: Completed
• Trial end date: 2010-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and tolerability of continuing vorinostat (MK-0683) dosing in cancer patients previously enrolled in one of five base studies (MK-0683-001, MK-0683-006, MK-0683-008, MK-0683-012, or MK-0683-013) who have shown benefit from receiving this drug.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Vorinostat

Criteria

Inclusion Criteria:

• Patient participated in one of the five vorinostat base protocols, has not shown tumor progression on that study, and has tolerated the study drug

• Patient did not withdraw from the base protocol

• Patient agrees to practice effective birth control during the study

Exclusion Criteria:

• Patient is receiving other standard and/or investigational anticancer therapy

• Patient has any condition or disease that would interfere with compliance or pose addition risk in administering the study drug